Randy Sweis to Urinary Bladder Neoplasms
This is a "connection" page, showing publications Randy Sweis has written about Urinary Bladder Neoplasms.
Connection Strength
4.101
-
Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival. Sci Rep. 2021 05 11; 11(1):9983.
Score: 0.572
-
FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. Front Immunol. 2020; 11:575258.
Score: 0.552
-
The Tumor Microenvironment of Bladder Cancer. Adv Exp Med Biol. 2020; 1296:275-290.
Score: 0.521
-
Methods to assess anticancer immune responses in orthotopic bladder carcinomas. Methods Enzymol. 2020; 635:127-137.
Score: 0.514
-
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24.
Score: 0.462
-
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol. 2016 12; 34(12):556-565.
Score: 0.419
-
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
Score: 0.405
-
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. Front Immunol. 2024; 15:1358019.
Score: 0.174
-
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
Score: 0.172
-
Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. Hum Pathol. 2020 12; 106:54-61.
Score: 0.137
-
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798.
Score: 0.129
-
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. Eur Urol Oncol. 2024 Aug; 7(4):933-943.
Score: 0.043